TRIPOD Checklist: Prediction Model Development and Validation

Section	Item		Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract					
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Page 1/Line 1-2.	"Wavelet Transform Can Enhance the CT Texture
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	Page 3-4/Line 41-67.	"Background: We aimed to develop and validate a
Introduction					
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Page 5-6/Line 71-98.	"The outbreak of coronavirus disease 2019
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	Page 6/Line 99-110.	"Radiomics, as a relatively mature medical image
Methods					
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, ifapplicable.	Page 7-8/Line 131-140.	"A total of 174 patients with COVID-19
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	Page 7/Line 131-133.	"A total of 174 patients
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	Page 7-8/Line 135-140.	"Finally, 187 pulmonary lesions of 111 patients
	5b	D;V	Describe eligibility criteria for participants.	Page 7/Line 133-135 and	See Figure 2. and "The
	5c	D;V	Give details of treatments received, if relevant.	N/A	Not relevant.
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	Page8/Line 141-149.	"The grade assessment was assessed by one
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	Page 10/Line 189-193	"Based on the machine
Predictors	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	Page 9/ Line 167-172., Table 4 and Figure 4.	See Table 4 and Figure 4. and "we extracted 73
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	Page 9-10/Line 191-193	"The optimal pipeline was
Sample size	8	D;V	Explain how the study size was arrived at.	Page 7/Line 117-129.	"The wavelet transforming

Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	N/A, see Figure 2.	After data exclusion, the included data were
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	Page10/ Line196-198.	"To facilitate clinical use,
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	Page 10/Line 194-198.	"Then, the final radiomic model was developed in
	10c	V	For validation, describe how the predictions were calculated.	Page10-11/Line 195-206	"Then, the final radiomic
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Page 10/ Line 189-198.	"Comparison of different
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	N/A	Not need model updating
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	N/A	No risk groups in the
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	Page 10-11/Line 199-206.	"Statistical analysis was mainly performed with R
Results					
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	Page28-29, Line 552-564, see Figure 1 and Figure 2.	Mainly see Figure 2.
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	Table 1, and Page 11/Line 209-214.	Table 1 and "As shown in Table 1, 80 (74.07%)
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	See Table 1, Table S1.	Table 1 and Table S1.
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	See Figure 2.	See Figure 2.
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	Figure 3 and Table 3.	Figure 3 and Table 3.
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	Figure 4. Page 31/ Line 572-580.	See Figure 4.
	15b	D	Explain how to the use the prediction model.	Figure 5. Page 30/Line	See Figure 5.
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	Page 11-12/ Line224-246. And see Figure3 and Table	"The comparison of wavelets transform models
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	N/A	Not need model-updating.
Discussion					
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	Page 15 /Line 302-317.	"In addition, we found the mean age of mild lesions

Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	Page 13-14/Line 248-262..	"In clinical practice, grade assessment of COVID-19
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	Page 13-14/Line 263-293.	"In the real world, there must be multi-vendor data
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	Page 15-16/Line 319-323.	"In conclusion, our study
Other information					
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	Supplementary Material	Supplementary Material
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	Page16/Line 327-331. See	"This work was financially

* Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

Article information:https://dx.doi.org/10.21037/qims-22-252
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.